John E Dowling

This inventor holds 10 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 2 EPO patents. Top assignees: Aldeyra Therapeutics, Inc., Aldexa Therapeutics, Inc., Neuron Systems, Inc.. Active years: 2011-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: John E Dowling. Retrieved from https://idiyas.com/inventor/john-e-dowling

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 10 (Patent Applications = 2)

% Patents Active = 100.0

CIPO Patents = 1

EPO Patents = 2 (Patent Applications = 2)

Average Co-Inventor Count = 3.0

ph-index = 9

Forward Citations = 246(Granted Patents)

Company Filing History:

7 out of 40

Aldeyra Therapeutics, Inc.

patents

2 out of 2

Aldexa Therapeutics, Inc.

Years Active: 2011-2023

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11724987 - Compositions and methods of treating retinal disease (2023-08-15),

2. 10913722 - Compositions and methods of treating retinal disease (2021-02-09),

3. 10202348 - Compositions and methods of treating retinal disease (2019-02-12),

4. 9896419 - Compositions and methods of treating retinal disease (2018-02-20),

5. 9650342 - Compositions and methods of treating retinal disease (2017-05-16),

6. 9364471 - Compositions and methods of treating retinal disease (2016-06-14),

7. 9265759 - Compositions and methods of treating retinal disease (2016-02-23),

8. 8940764 - Compositions and methods of treating retinal disease (2015-01-27),

9. 8940721 - Compositions and methods of treating retinal disease (2015-01-27),

10. 7973025 - Compositions and methods of treating retinal disease (2011-07-05),

Title: Innovations by John E Dowling

Introduction

John E Dowling is a prominent inventor based in Boston, MA, known for his significant contributions to the field of retinal disease treatment. With a total of 10 patents to his name, Dowling has made remarkable strides in developing compositions and methods aimed at addressing various forms of retinal diseases.

Latest Patents

Among his latest patents, Dowling has focused on compositions and methods for treating macular degeneration and other retinal diseases. His work specifically targets the accumulation of A2E and lipofuscin, providing innovative solutions for preventing their formation and accumulation. These advancements are crucial in the ongoing battle against retinal diseases that affect countless individuals.

Career Highlights

Throughout his career, John E Dowling has worked with notable companies such as Aldeyra Therapeutics, Inc. and Aldexa Therapeutics, Inc. His expertise and dedication have positioned him as a key figure in the development of therapeutic solutions for retinal conditions.

Collaborations

Dowling has collaborated with esteemed colleagues, including Thomas A Jordan and John Clifford Chabala, further enhancing the impact of his work in the field of retinal disease treatment.

Conclusion

John E Dowling's innovative contributions to retinal disease treatment through his patents and collaborations highlight his importance in the medical field. His ongoing efforts continue to pave the way for advancements that can significantly improve the quality of life for those affected by these conditions.

Profile summary based on public USPTO records.